US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Medicus Pharma Ltd.

2.09

+0.210011.17%

Volume:503.01K

Turnover:1.00M

Market Cap:37.24M

PE:-1.53

High:2.09

Open:1.92

Low:1.82

Close:1.88

52wk High:8.94

52wk Low:1.79

Shares:17.82M

Float Shares:9.74M

Volume Ratio:1.58

T/O Rate:5.16%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-1.3692

EPS(LYR):-1.1597

ROE:-352.45%

ROA:-102.95%

PB:11.46

PE(LYR):-1.80

Loading ...

Overview Company News Filings

Medicus Pharma Ltd. Files Initial Statement of Beneficial Ownership for Director Patrick J. Mahaffy

Medicus Pharma Ltd. Advances Clinical Trials for Skin Cancer Treatment

Medicus Pharma Ltd. Launches SKNJCT-004 Phase 2 Clinical Study in UAE for Non-Invasive Basal Cell Carcinoma Treatment

Medicus Pharma Is Maintained at Buy by D. Boral Capital

Medicus Pharma Ltd. Completes Acquisition of Antev Limited, Expanding Drug Development Pipeline

Medicus Pharma Reports Q2 Net Loss of $6.2 Million, Total Operating Expenses Surge to $6.0 Million

Medicus Pharma Is Maintained at Buy by D. Boral Capital

Medicus Pharma Ltd. Announces Ongoing SKNJCT-003 Phase 2 Clinical Study for Basal Cell Carcinoma and Expansion to European Sites

Medicus Pharma Is Maintained at Buy by D. Boral Capital

BRIEF-Medicus Pharma Ltd - Co And Helixnano Enter MoU For Vaccine Development - SEC Filing

Medicus Pharma Ltd - Co and Helixnano Enter Mou for Vaccine Development - SEC Filing

THOMSON REUTERS

Medicus Pharma Ltd. Announces New Clinical Study for Thermostable mRNA Vaccine Utilizing Innovative Microneedle Array Technology

Medicus Pharma Ltd. Files Initial Statement of Beneficial Ownership for Director Cathy McMorris Rodgers

Medicus Pharma Ltd. Appoints Deloitte as Lead Adviser for Doxorubicin Microneedle Array Licensing Deal

Medicus Pharma Ltd. Appoints Congresswoman Cathy McMorris Rodgers and Ajay Raju to Board of Directors

Medicus Pharma Ltd. Announces Expansion of SKNJCT-003 Clinical Trial and Plans Acquisition of UK-Based Antev Ltd

Medicus Pharma Ltd. Engages in Share Transactions: Issues 490,000 Shares to Yorkville and Sells 1,340,000 Warrants with New Inducement Agreement

Medicus Pharma Is Maintained at Buy by D. Boral Capital

Medicus Pharma Ltd. Seeks FDA Fast-Track Approval for Innovative Skin Cancer Treatment with Dissolvable Doxorubicin Microneedle Arrays

Medicus Pharma Ltd. Files Initial Beneficial Ownership Statement for Andrew Alasdair Smith, Chief Operating Officer

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/MDCX/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MDCX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MDCX\",,,,,undefined,":{"symbol":"MDCX","market":"US","secType":"STK","nameCN":"Medicus Pharma Ltd.","latestPrice":2.09,"timestamp":1757361600000,"preClose":1.88,"halted":0,"volume":503008,"delay":0,"floatShares":9740000,"shares":17816266,"eps":-1.369182,"marketStatus":"Pre-Mkt","change":0.21,"latestTime":"09-09 06:43:55 EDT","open":1.92,"high":2.09,"low":1.82,"amount":1004016.9959072,"amplitude":0.143617,"askPrice":2.24,"askSize":100,"bidPrice":1.98,"bidSize":9261,"shortable":3,"etf":0,"ttmEps":-1.369182,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1757424600000},"marketStatusCode":1,"adr":0,"listingDate":1731560400000,"exchange":"NASDAQ","adjPreClose":2.09,"postHourTrading":{"tag":"盘后","latestPrice":1.95,"preClose":2.09,"latestTime":"19:12 EDT","volume":7468,"amount":15115.8042,"timestamp":1757373163016},"volumeRatio":1.5816767386487895},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MDCX\",,,,,undefined,":{"symbol":"MDCX","floatShares":9740000,"roa":"-102.95%","roe":"-352.45%","lyrEps":-1.159715,"volumeRatio":1.5816767386487895,"shares":17816266,"dividePrice":0,"high":2.09,"amplitude":0.143617,"preClose":1.88,"low":1.82,"week52Low":1.7901,"pbRate":"11.46","week52High":8.94,"institutionHeld":0,"latestPrice":2.09,"committee":0.978635,"eps":-1.369182,"divideRate":0,"volume":503008,"delay":0,"ttmEps":-1.369182,"open":1.92,"prevYearClose":2.43,"prevWeekClose":1.88,"prevMonthClose":1.94,"prevQuarterClose":2.99,"fiveDayClose":1.94,"twentyDayClose":1.97,"sixtyDayClose":2.67},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MDCX\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MDCX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"MDCX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":3,"updateTime":1744862400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/MDCX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"MDCX","date":"2025-09-05","current":-1.907346,"percent":1,"low":-2.313829,"twenty":-2.205434,"median":-2.115799,"eighty":-2.053263,"high":-1.907346,"avg":-2.119273,"sd":0.114596,"marketCap":32603766},"quantilePoints":[{"date":"2025-08-29","current":-2.084531,"twenty":-2.272139,"median":-2.126221,"eighty":-2.109545,"marketCap":35632532},{"date":"2025-09-05","current":-1.907346,"twenty":-2.205434,"median":-2.115799,"eighty":-2.053263,"marketCap":32603766}],"updateTime":1757389139034},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MDCX\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2566632498","title":"Medicus Pharma Ltd. Files Initial Statement of Beneficial Ownership for Director Patrick J. Mahaffy","url":"https://stock-news.laohu8.com/highlight/detail?id=2566632498","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566632498?lang=en_us&edition=fundamental","pubTime":"2025-09-09 04:37","pubTimestamp":1757363836,"startTime":"0","endTime":"0","summary":"Medicus Pharma Ltd. has filed an initial statement of beneficial ownership, identifying Patrick J. Mahaffy as a Director of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medicus Pharma Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on September 08, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250908:nNDLSRy5X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCX","BK4139"],"gpt_icon":0},{"id":"2565684770","title":"Medicus Pharma Ltd. Advances Clinical Trials for Skin Cancer Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2565684770","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2565684770?lang=en_us&edition=fundamental","pubTime":"2025-09-08 21:10","pubTimestamp":1757337059,"startTime":"0","endTime":"0","summary":"Medicus Pharma Ltd ( ($MDCX) ) has issued an announcement. Medicus Pharma Ltd. announced the commencement of patient recruitment for its SKNJCT-004...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/medicus-pharma-ltd-advances-clinical-trials-for-skin-cancer-treatment?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/medicus-pharma-ltd-advances-clinical-trials-for-skin-cancer-treatment?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MDCX","BK4139"],"gpt_icon":0},{"id":"2565685295","title":"Medicus Pharma Ltd. Launches SKNJCT-004 Phase 2 Clinical Study in UAE for Non-Invasive Basal Cell Carcinoma Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2565685295","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2565685295?lang=en_us&edition=fundamental","pubTime":"2025-09-08 19:30","pubTimestamp":1757331050,"startTime":"0","endTime":"0","summary":"Medicus Pharma Ltd. has announced the commencement of the SKNJCT-004 phase 2 clinical study aimed at non-invasively treating basal cell carcinoma  of the skin. The study has begun recruiting participants at Cleveland Clinic Abu Dhabi and plans to include up to 36 subjects across multiple sites in the United Arab Emirates. This randomized, double-blind, placebo-controlled study will evaluate the efficacy of two dose levels of D-MNA compared to a placebo. Results of this study will be presented in the future. The company is also conducting a related study, SKNJCT-003, in the United States and Europe, which has shown promising interim results with over 60% clinical clearance.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medicus Pharma L","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250908:nNDL2K1Z6k:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCX","BK4139"],"gpt_icon":0},{"id":"2564800498","title":"Medicus Pharma Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2564800498","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564800498?lang=en_us&edition=fundamental","pubTime":"2025-09-02 21:12","pubTimestamp":1756818720,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MDCX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  September 02, 2025 09:12 ET (13:12 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCX"],"gpt_icon":0},{"id":"2564540801","title":"Medicus Pharma Ltd. Completes Acquisition of Antev Limited, Expanding Drug Development Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2564540801","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564540801?lang=en_us&edition=fundamental","pubTime":"2025-09-02 19:31","pubTimestamp":1756812695,"startTime":"0","endTime":"0","summary":"Medicus Pharma Ltd. has completed the acquisition of 98.6% of Antev Limited's issued and outstanding shares, a move that bolsters its drug development pipeline. The transaction involved approximately US$2.97 million in cash and 1,603,164 common shares of Medicus. Antev, a UK-based clinical-stage drug development company, is advancing Teverelix, a next generation GnRH antagonist aimed at treating acute urinary retention and advanced prostate cancer, representing a US$6 billion market opportunity. Following the acquisition, Patrick J. Mahaffy, former Chairman of Antev, joins the Medicus Board of Directors. Dr. Paul Marchetto and Dr. Faisal Mehmud have been appointed Co-Chairmen of Antev's Board, while Amit Kohli remains the Interim CEO. Dr. Raza Bokhari, Executive Chairman & CEO of Medicus, expressed confidence in Teverelix's potential as a first-in-class product.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250902:nNDL4pTzgs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCX","BK4139"],"gpt_icon":0},{"id":"2561240009","title":"Medicus Pharma Reports Q2 Net Loss of $6.2 Million, Total Operating Expenses Surge to $6.0 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2561240009","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2561240009?lang=en_us&edition=fundamental","pubTime":"2025-08-23 04:31","pubTimestamp":1755894717,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medicus Pharma Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on August 22, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250822:nNDL2Cz62v:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCX"],"gpt_icon":0},{"id":"2561476628","title":"Medicus Pharma Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2561476628","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2561476628?lang=en_us&edition=fundamental","pubTime":"2025-08-22 19:15","pubTimestamp":1755861300,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MDCX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  August 22, 2025 07:15 ET (11:15 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCX"],"gpt_icon":0},{"id":"2561946443","title":"Medicus Pharma Ltd. Announces Ongoing SKNJCT-003 Phase 2 Clinical Study for Basal Cell Carcinoma and Expansion to European Sites","url":"https://stock-news.laohu8.com/highlight/detail?id=2561946443","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2561946443?lang=en_us&edition=fundamental","pubTime":"2025-08-21 19:31","pubTimestamp":1755775876,"startTime":"0","endTime":"0","summary":"Medicus Pharma Ltd. Announces Ongoing SKNJCT-003 Phase 2 Clinical Study for Basal Cell Carcinoma and Expansion to European Sites. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medicus Pharma Ltd. published the original content used to generate this news brief via Newsfile  on August 21, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250821:nNDL9SxB49:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCX","BK4139"],"gpt_icon":0},{"id":"2559798371","title":"Medicus Pharma Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2559798371","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559798371?lang=en_us&edition=fundamental","pubTime":"2025-08-14 00:18","pubTimestamp":1755101880,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MDCX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  August 13, 2025 12:18 ET (16:18 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCX"],"gpt_icon":0},{"id":"2556389049","title":"BRIEF-Medicus Pharma Ltd - Co And Helixnano Enter MoU For Vaccine Development - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2556389049","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2556389049?lang=en_us&edition=fundamental","pubTime":"2025-08-04 20:13","pubTimestamp":1754309602,"startTime":"0","endTime":"0","summary":"BRIEF-Medicus Pharma Ltd - Co And Helixnano Enter MoU For Vaccine Development - SEC FilingAug 4  - Medicus Pharma Ltd MDCX.O:MEDICUS PHARMA LTD - CO AND HELIXNANO ENTER MOU FOR VACCINE DEVELOPMENT - SEC FILINGMEDICUS PHARMA LTD - CO AND HELIXNANO TO COLLABORATE ON MRNA VACCINE-LOADED MNAS PRODUCTION THROUGH JV - SEC FILINGFurther company coverage: MDCX.O ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250804:nFWN3TW0Q3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MDCX"],"gpt_icon":0},{"id":"2556386945","title":"Medicus Pharma Ltd - Co and Helixnano Enter Mou for Vaccine Development - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2556386945","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2556386945?lang=en_us&edition=fundamental","pubTime":"2025-08-04 19:37","pubTimestamp":1754307458,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250804:nFWN3TW0Q3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MDCX"],"gpt_icon":0},{"id":"2556981386","title":"Medicus Pharma Ltd. Announces New Clinical Study for Thermostable mRNA Vaccine Utilizing Innovative Microneedle Array Technology","url":"https://stock-news.laohu8.com/highlight/detail?id=2556981386","media":"Reuters","labels":["corporation","productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2556981386?lang=en_us&edition=fundamental","pubTime":"2025-08-04 19:31","pubTimestamp":1754307065,"startTime":"0","endTime":"0","summary":"Medicus Pharma Ltd. Announces New Clinical Study for Thermostable mRNA Vaccine Utilizing Innovative Microneedle Array Technology. Medicus Pharma Ltd. has announced a new clinical study, in collaboration with Helix Nanotechnologies Inc., to explore the efficacy and safety of a thermostable mRNA-based vaccine using a proprietary Microneedle array  delivery platform. The study will compare the safety and preliminary efficacy of intramuscular injection versus intradermal MNA delivery of HelixNano's vaccine candidate, HN-0001, as part of a Phase 1 clinical bridging study. The study aims to assess the innovative combination of HelixNano's mRNA vaccine platform with Medicus' MNA technology. Results from this clinical study are anticipated to be presented in the future, contingent upon the successful formation of a joint venture between the two companies.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accur","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250804:nNDL34xW2N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCX","BK4139"],"gpt_icon":0},{"id":"2555831196","title":"Medicus Pharma Ltd. Files Initial Statement of Beneficial Ownership for Director Cathy McMorris Rodgers","url":"https://stock-news.laohu8.com/highlight/detail?id=2555831196","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555831196?lang=en_us&edition=fundamental","pubTime":"2025-07-31 22:36","pubTimestamp":1753972609,"startTime":"0","endTime":"0","summary":"Medicus Pharma Ltd. has filed an initial statement of beneficial ownership. The filing names Cathy McMorris Rodgers as the beneficial owner in the role of Director. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medicus Pharma Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on July 31, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250731:nNDL8j7myx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCX","BK4139"],"gpt_icon":0},{"id":"2555048404","title":"Medicus Pharma Ltd. Appoints Deloitte as Lead Adviser for Doxorubicin Microneedle Array Licensing Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2555048404","media":"Reuters","labels":["executive","corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555048404?lang=en_us&edition=fundamental","pubTime":"2025-07-30 18:57","pubTimestamp":1753873054,"startTime":"0","endTime":"0","summary":"Medicus Pharma Ltd. has entered into a new engagement with Deloitte LLP, appointing the firm as the exclusive lead financial adviser. The collaboration aims to identify one or more partners for an out-licensing transaction involving Doxorubicin Microneedle Array , a treatment for Basal Cell Carcinoma in adults. This agreement allows for flexibility in the transaction structure, which may include licensing or other mechanisms. Medicus Pharma Ltd. will compensate Deloitte with a retainer and a contingent success fee upon the successful completion of a transaction.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medicus Pharma Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Ana","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250730:nNDL6brvM1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MDCX"],"gpt_icon":0},{"id":"2553221776","title":"Medicus Pharma Ltd. Appoints Congresswoman Cathy McMorris Rodgers and Ajay Raju to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2553221776","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553221776?lang=en_us&edition=fundamental","pubTime":"2025-07-23 19:31","pubTimestamp":1753270295,"startTime":"0","endTime":"0","summary":"Medicus Pharma Ltd. has announced new additions to its board of directors following the company's annual and special meeting of shareholders. Congresswoman Cathy McMorris Rodgers and Ajay Raju, Esq., have been elected as new members. The meeting, held on July 22, 2025, in Toronto, Ontario, resulted in all eight nominees for the board being elected.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medicus Pharma Ltd. published the original content used to generate this news brief via Newsfile  on July 23, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250723:nNDLbKXzpC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MDCX"],"gpt_icon":0},{"id":"2553479621","title":"Medicus Pharma Ltd. Announces Expansion of SKNJCT-003 Clinical Trial and Plans Acquisition of UK-Based Antev Ltd","url":"https://stock-news.laohu8.com/highlight/detail?id=2553479621","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553479621?lang=en_us&edition=fundamental","pubTime":"2025-07-21 19:31","pubTimestamp":1753097473,"startTime":"0","endTime":"0","summary":"Medicus Pharma Ltd. has announced an expansion of its Phase 2 clinical study for SKNJCT-003, which began randomizing patients in August 2024 across nine clinical sites in the United States. Following a positively trending interim analysis in March 2025, showing over 60% clinical clearance, the investigational review board has increased the number of study participants to 90 subjects. The interim results are preliminary and may not necessarily reflect the final study outcomes. Additionally, the company is expanding its clinical trial sites into Europe. The lead asset, SkinJect Inc., focuses on a novel treatment for non-melanoma skin cancer using a patented dissolvable doxorubicin-containing microneedle array. Furthermore, Medicus Pharma Ltd. will present at the BTIG Virtual Biotech Conference 2025, where Dr. Raza Bokhari, Executive Chairman and CEO, will participate in a fireside chat on July 30, 2025. The chat will be livestreamed for registered investors, and a recording will be avail","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250721:nNDL4Q7Fwv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MDCX"],"gpt_icon":0},{"id":"2551090189","title":"Medicus Pharma Ltd. Engages in Share Transactions: Issues 490,000 Shares to Yorkville and Sells 1,340,000 Warrants with New Inducement Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2551090189","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551090189?lang=en_us&edition=fundamental","pubTime":"2025-07-14 20:59","pubTimestamp":1752497966,"startTime":"0","endTime":"0","summary":"Medicus Pharma Ltd. Engages in Share Transactions: Issues 490,000 Shares to Yorkville and Sells 1,340,000 Warrants with New Inducement Agreement. Medicus Pharma Ltd. recently engaged in share transactions with YA II PN, Ltd.  under a Standby Equity Purchase Agreement . On July 9 and July 14, 2025, the company sold a total of 490,000 common shares to Yorkville. The shares were sold at approximately $3.2841 and $3.0216 per share, amounting to total proceeds of approximately $1,521,000. Additionally, the company entered into an inducement agreement with an accredited holder to exercise existing warrants for up to 1,340,000 shares, generating gross proceeds of approximately $3.75 million.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medi","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250714:nNDL38zQpf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MDCX"],"gpt_icon":0},{"id":"2550663026","title":"Medicus Pharma Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2550663026","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550663026?lang=en_us&edition=fundamental","pubTime":"2025-07-09 21:05","pubTimestamp":1752066300,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MDCX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 09, 2025 09:05 ET (13:05 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCX"],"gpt_icon":0},{"id":"2549627541","title":"Medicus Pharma Ltd. Seeks FDA Fast-Track Approval for Innovative Skin Cancer Treatment with Dissolvable Doxorubicin Microneedle Arrays","url":"https://stock-news.laohu8.com/highlight/detail?id=2549627541","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549627541?lang=en_us&edition=fundamental","pubTime":"2025-07-08 19:31","pubTimestamp":1751974291,"startTime":"0","endTime":"0","summary":"Medicus Pharma Ltd. Seeks FDA Fast-Track Approval for Innovative Skin Cancer Treatment with Dissolvable Doxorubicin Microneedle Arrays. Medicus Pharma Ltd. has announced the submission of a Type C meeting request to the U.S. Food and Drug Administration  as part of its efforts to fast-track the clinical development program for treating Basal Cell Carcinoma  of the skin using Dissolvable Doxorubicin-containing Microneedle Arrays . The meeting, anticipated for the week of October 6th, 2025, aims to discuss the D-MNA product development and secure the FDA's consent to accelerate the clinical pathway. The company is seeking the FDA's feedback on various aspects, including the selected doses for future studies and the appropriateness of the primary endpoint for upcoming trials. This development is a significant step in Medicus Pharma's ongoing regulatory review process.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strive","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250708:nNDL3zr5Md:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MDCX"],"gpt_icon":0},{"id":"2548179338","title":"Medicus Pharma Ltd. Files Initial Beneficial Ownership Statement for Andrew Alasdair Smith, Chief Operating Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2548179338","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548179338?lang=en_us&edition=fundamental","pubTime":"2025-07-04 06:37","pubTimestamp":1751582278,"startTime":"0","endTime":"0","summary":"Medicus Pharma Ltd. has filed an initial statement of beneficial ownership with the United States Securities and Exchange Commission. The filing mentions Andrew Alasdair Smith as the beneficial owner, who serves as the Chief Operating Officer of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medicus Pharma Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on July 03, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250703:nNDLLZpl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCX"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":41,"code":"91000000","status":"200"}]}}